When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IPSEF - European Commission OKs Exelixis and Ipsen's Cabometyx for second-line liver cancer
Ipsen Sa Ord
Exelixis (NASDAQ:EXEL) announces that collaboration partner Ipsen (OTCPK:IPSEF) has received marketing approval from the European Commission for CABOMETYX (cabozantinib) as monotherapy in adult patients with hepatocellular carcinoma who have been previously treated with Bayer's Nexavar (sorafenib).
More news on: Exelixis, Inc., Ipsen S.A., Healthcare stocks news,